Novel monoclonal antibody shows promise against ovarian cancer
MedWire News: A novel monoclonal antibody may, with the help of natural killer cells, reduce the resistance of ovarian cancer to the tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), and increase apoptosis, scientists have found.
To determine the effect of the monoclonal TRAILR2 (DR2) agonistic antibody AD5-10, Michael Krainer, from the Medical University of Vienna in Austria, and colleagues conducted a series of experiments using ovarian cancer cell lines and mouse models.
Both in vitro and in vivo, the presence of AD5-10 with TRAIL and natural killer cells expressing TRAIL resulted in re-sensitization of ovarian cancer cells to apoptosis. The combination of AD5-10 and the chemotherapy drug carboplatin had a greater than additive effect in vitro.
The results also showed that, in vivo, AD5-10 was able to restore the sensitivity of platin-resistant ovarian cancer to carboplatin. However, depletion of natural killer cells abolished the anti-tumor effect of AD5-10, suggesting that TRAIL may mediate the effects of natural killers cells against ovarian cancer.
Discussing the effects of AD5-10, Professor Krainer said: “It actually works! We were able to show in both cell cultures and animal models that TRAIL-resistant ovarian cancer tumour cells become sensitive to TRAIL again if TRAIL and AD5-10 are both present at the same time.”
MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2010
By Liam Davenport